The Motley Fool

Why the Next Science share price has more than tripled in 2019

The Next Science Ltd (ASX: NXS) share price has more than tripled to $3.09 since its April 2019 initial public offering at $1 per share.

Today the group reported an operating cash loss of US$3.43 million on revenue of US$1.2 million for the quarter ending June 30, 2019. 

Next Science already has four anti-bacterial FDA-approved products (used to treat common wounds or lacerations) in the U.S. market under its ‘Xbio Family’ generic label.

Like any good ASX biotech, it also has multiple new products in the pipeline for potential FDA approval and commercialisation.

It also has an acne treatment product it expects to launch in Australia in the second half of 2019 and reported today that it has made significant progress over the first half of 2019 in getting more products approved. 

It has US$23.9 million cash on hand as at June 30 2019 to meet its cash outflows and fund its upcoming and ongoing clinical trials. Notably these can be expensive. 

Next Science currently has a market cap around $550 million, which looks very high to me relative to its cash flows.

Another speccy biotech widely fancied by punters to hit the big time is Paradigm Group Ltd (ASX: PAR). It could be worth more research for anyone with a high risk tolerance. 

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more


Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

FREE REPORT: Five Cheap and Good Stocks to Buy now…

Our Motley Fool experts have FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.